We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Aneurysm Genetic Risk in Patients With QIB Changes (AnGen)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05317169
Recruitment Status : Recruiting
First Posted : April 7, 2022
Last Update Posted : April 7, 2022
Information provided by (Responsible Party):
Aichi Chien, PhD, University of California, Los Angeles

Brief Summary:

Intracranial aneurysm rupture is a leading cause of hemorrhagic strokes which carry high mortality and disability rates as well as high healthcare costs. Unruptured intracranial aneurysms (UIA) are common in the general population, occurring in 1-2% of individuals. Previous studies have shown that UIA growth and rupture are strongly associated with each other, with growing aneurysms 9-12 times more likely to rupture, and nearly all aneurysms growing prior to rupture. Thanks to advanced medical imaging, UIA are now more and more often detected incidentally. However not all aneurysms qualify for preventive surgical or interventional procedures according to current International Study of Unruptured Intracranial Aneurysms (ISUIA) guidelines, and some must therefore be monitored for growth. Current guidelines are based heavily on size, an inconsistent predictor of future growth. To improve management strategies for individual patients and more comprehensively assess aneurysm risk, the investigators propose to identify risk factors related to growth.

Aneurysm etiology is multifactorial, with both genetic and environmental contributions to aneurysm formation, growth, and rupture. Exploring new risk factors based on aneurysm natural history and understanding the mechanisms underlying aneurysm rupture have been extensive research areas. As previous studies have shown that quantitative imaging biomarkers (QIB) can provide a more accurate assessment of the characteristics of aneurysms, the investigators propose a combined study which identifies QIB associated with aneurysm growth to identify factors related to growth.

Condition or disease
Brain Aneurysm

Detailed Description:

The objective of this study is to investigate intracranial aneurysms that have been followed with clinical 3D aneurysm images and create a matrix that can identify the risk of growth by integrating QIB with genetic predisposition risk factors. 70 Patients who have been followed by clinical aneurysm imaging study will be enrolled in this study. The study team will collect blood samples from the patients for genetic analysis.

To find the genetic factors, the blood samples will be processed with a focus on genetic variants 1) in pathways involved in endothelial and vascular function and 2) previously identified in genome-wide association studies of aneurysm risk. These analyses will include both common polymorphisms and rare alterations. These biomarkers have important implications for facilitating identification of high-risk subgroups for aneurysm growth and the development of improved evidence-based decision-making.

The investigators will perform aneurysm 3D analysis based on the aneurysm images to extract aneurysm QIB for these cases. Shape parameters such as aneurysm surface area shape indices will be collected for individual aneurysms as well as parameters capturing the aneurysm blood flow pattern. The study plans to address whether certain genetic variants for vascular function are present in patients with QIB change over time.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 70 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Aneurysm Genetic Risk in Patients With Changes in Quantitative Imaging Biomarkers Over Time
Actual Study Start Date : December 12, 2018
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : June 30, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Aneurysms

Primary Outcome Measures :
  1. Quantitative imaging biomarkers (QIB) change [ Time Frame: 3 years ]
    Number of participants with changes in quantitative imaging biomarkers

Secondary Outcome Measures :
  1. Genetic biomarkers in QIB change [ Time Frame: 3 years ]
    Number of participants with genetic biomarkers

Biospecimen Retention:   Samples With DNA
whole blood

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
UCLA patients who come for yearly CT or MR angiography for cerebral aneurysm surveillance.

Inclusion Criteria:

Patients with unruptured cerebral aneurysms followed yearly using non-invasive imaging techniques including CT and MR angiography.

Exclusion Criteria:

Patients with bleeding disorders. Patients who have severe intravenous CT or MR contrast allergy. Patients with evidence of kidney failure. Patients with severe claustrophobia. Patients with religious objections to phlebotomy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05317169

Layout table for location contacts
Contact: Aichi Chien, PhD 310-267-6837 achien@mednet.ucla.edu

Layout table for location information
United States, California
University of California, Los Angeles Recruiting
Los Angeles, California, United States, 90024
Contact: Aichi Chien, PhD       achien@mednet.ucla.edu   
Contact: Victoria Rueda    310-562-9694    vrueda@mednet.ucla.edu   
Principal Investigator: Aichi Chien, PhD         
Sub-Investigator: Gary Duckwiler, MD         
Sub-Investigator: Viktor Szeder, MD         
Sub-Investigator: Geoffrey Colby, MD         
Sponsors and Collaborators
University of California, Los Angeles
Layout table for investigator information
Principal Investigator: Aichi Chien, PhD University of California, Los Angeles
Layout table for additonal information
Responsible Party: Aichi Chien, PhD, Professor, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT05317169    
Other Study ID Numbers: 16-001867
First Posted: April 7, 2022    Key Record Dates
Last Update Posted: April 7, 2022
Last Verified: April 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Aichi Chien, PhD, University of California, Los Angeles:
Brain Aneurysm
Ruptured Brain Aneurysm
Aneurysm Growth
Brain Aneurysm Genetic Markers
Vascular Malformation
Additional relevant MeSH terms:
Layout table for MeSH terms
Intracranial Aneurysm
Vascular Diseases
Cardiovascular Diseases
Intracranial Arterial Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases